Oncolytic virotherapy in upper gastrointestinal tract cancers.

IF 6.7 Oncolytic Virotherapy Pub Date : 2018-03-23 eCollection Date: 2017-01-01 DOI:10.2147/OV.S161397
Raquel Yokoda, Bolni M Nagalo, Mansi Arora, Jan B Egan, James M Bogenberger, Thomas T DeLeon, Yumei Zhou, Daniel H Ahn, Mitesh J Borad
{"title":"Oncolytic virotherapy in upper gastrointestinal tract cancers.","authors":"Raquel Yokoda, Bolni M Nagalo, Mansi Arora, Jan B Egan, James M Bogenberger, Thomas T DeLeon, Yumei Zhou, Daniel H Ahn, Mitesh J Borad","doi":"10.2147/OV.S161397","DOIUrl":null,"url":null,"abstract":"Upper gastrointestinal tract malignancies are among the most challenging cancers with regard to response to treatment and prognosis. Cancers of the esophagus, stomach, pancreas, liver, and biliary tree have dismal 5-year survival, and very modest improvements in this rate have been made in recent times. Oncolytic viruses are being developed to address these malignancies, with a focus on high safety profiles and low off-target toxicities. Each viral platform has evolved to enhance oncolytic potency and the clinical response to either single-agent viral therapy or combined viral treatment with radiotherapy and chemotherapy. A panel of genomic alterations, chimeric proteins, and pseudotyped capsids are the breakthroughs for vector success. This article revisits developments for each viral platform to each tumor type, in an attempt to achieve maximum tumor selectivity. From the bench to clinical trials, the scope of this review is to highlight the beginnings of translational oncolytic virotherapy research in upper gastrointestinal tract malignancies and provide a bioengineering perspective of the most promising platforms.","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":null,"pages":null},"PeriodicalIF":6.7000,"publicationDate":"2018-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S161397","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncolytic Virotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OV.S161397","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8

Abstract

Upper gastrointestinal tract malignancies are among the most challenging cancers with regard to response to treatment and prognosis. Cancers of the esophagus, stomach, pancreas, liver, and biliary tree have dismal 5-year survival, and very modest improvements in this rate have been made in recent times. Oncolytic viruses are being developed to address these malignancies, with a focus on high safety profiles and low off-target toxicities. Each viral platform has evolved to enhance oncolytic potency and the clinical response to either single-agent viral therapy or combined viral treatment with radiotherapy and chemotherapy. A panel of genomic alterations, chimeric proteins, and pseudotyped capsids are the breakthroughs for vector success. This article revisits developments for each viral platform to each tumor type, in an attempt to achieve maximum tumor selectivity. From the bench to clinical trials, the scope of this review is to highlight the beginnings of translational oncolytic virotherapy research in upper gastrointestinal tract malignancies and provide a bioengineering perspective of the most promising platforms.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
上消化道肿瘤的溶瘤病毒治疗。
就治疗反应和预后而言,上胃肠道恶性肿瘤是最具挑战性的癌症之一。食道癌、胃癌、胰腺癌、肝癌和胆道癌的5年生存率很低,近年来生存率略有提高。正在开发溶瘤病毒来治疗这些恶性肿瘤,重点是高安全性和低脱靶毒性。每种病毒平台都在不断发展,以增强溶瘤效力和对单药病毒治疗或病毒联合放疗和化疗的临床反应。一组基因组改变、嵌合蛋白和假型衣壳是载体成功的突破。本文回顾了针对每种肿瘤类型的每种病毒平台的发展,试图实现最大的肿瘤选择性。从实验室到临床试验,本综述的范围是强调上胃肠道恶性肿瘤的转化溶瘤病毒治疗研究的开始,并提供最有前途的生物工程平台的观点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
期刊最新文献
The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment. Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib. Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development. Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus. Virus-Receptor Interactions: Structural Insights For Oncolytic Virus Development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1